key: cord-0898132-lvuckqbk
authors: Metbulut, Azize Pınar; Özkaya Parlakay, Aslınur; Bayhan, Gülsüm İclal; Kanık Yüksek, Saliha; Gülhan, Belgin; Şengül Emeksiz, Zeynep; Şenel, Emrah; Dibek Mısırlıoğlu, Emine
title: Evaluation of cutaneous symptoms in children infected with COVID‐19
date: 2021-03-08
journal: Pediatr Allergy Immunol
DOI: 10.1111/pai.13467
sha: 5d0dc72b3f0de6d66e74cb39e5f915b6815bc6a9
doc_id: 898132
cord_uid: lvuckqbk

Severe acute respiratory syndrome causing coronavirus (SARS-CoV-2) is a new corona virus responsible for the pandemic named Coronavirus Disease 2019(COVID-19). Although the pathogenesis of the disease has not been completely understood yet, it may cause clinical pictures with various degrees of multisystem involvement(1,2).

To the Editor, Severe acute respiratory syndrome causing coronavirus (SARS-CoV-2) is a new coronavirus responsible for the pandemic named coronavirus disease 2019 . Although the pathogenesis of the disease has not been completely understood yet, it may cause clinical pictures with various degrees of multisystem involvement. 1, 2 Studies have indicated that coronavirus can also cause cutaneous lesions; however, specific cutaneous symptoms of COVID-19 infection have not been disclosed yet. The prevalence of cutaneous manifestations in COVID-19 patients was between 0.2% and 20.4%

in the recently published studies 1,3-6 and 3.4% in a review including 28 studies where the patients aged between 0 and 18 years age had COVID-19. 2 In this respect, we aimed to analyze the incidence and the types of cutaneous manifestations associated with COVID-19 infections in pediatric patients.

Children who were diagnosed COVID-19 in Ankara City Hospital,

Children's Hospital in Turkey between March 11 and September 30, 2020, were evaluated in this prospective study. The study protocol was approved by the Institutional Ethics Committee of Ankara City Hospital (E1-20-546).

Of the 5143 children infected with SARS-CoV-2, only 13 (0.25%) developed cutaneous lesions during the period of study. The median age of those children was 80 months (IQR: 19-118.5 months), and 10 of them were boys (76.90%) ( Table 1 ). Only 2 of the patients had a chronic disease; epilepsy; and undefined immunodeficiency (Tables 1 and 2) . Table 2 ).

In our study, there were six patients with a history of drug usage.

We terminated the usage of any suspicious drug due to the rash in combination with the medication history of the patient. The aforementioned patients did not have any reported history of drug allergy.

On the second day of the treatment and after 2 hours of the dose, maculopapular exanthema was observed in the trunk, face, and legs of the patient who was treated with hydroxychloroquine. The hydroxychloroquine treatment was terminated in 1 day (patient nine). termination of the ampicillin-sulbactam treatment, rashes were revealed in 1 day while favipiravir treatment was continued (patient three) ( Table 2 ). It was observed that one of the patient has developed

DRESS. An eight-year-old boy having epilepsy disease presented with fever, cough, and rashes in trunk, face, and lower extremities.

The patient was on the ninth day of amoxicillin-clavulanic acid treatment and on the 19th day of carbamazepine treatment when the rash started. In his laboratory findings, serum transaminases and eosinophil level were elevated and viral markers were negative.

Hence, the carbamazepine treatment and amoxicillin-clavulanic acid treatment were terminated. He received levetiracetam treatment for epilepsy (patient ten) ( Table 2) .

One patient was presented with SJS. The patient was prescribed amoxicillin-clavulanate for complaints of fever, throat pain, and cough. After 2 days of amoxicillin-clavulanate usage, he applied to the hospital with fever, maculopapular lesions, mucosal lesions in oral and anal mucosa, blistering cutaneous lesions, vesicles and bullae with desquamation commonly affecting the face, scalp, and neck, and anterior chest wall and back. Nikolsky's sign was positive. Also, severe respiratory distress was examined (patient eleven) ( Table 2 ).

In one patient, COVID-19 infection was presented with cough and fever. Erythema nodosum developed at the bilateral extensor surface of the hands and pretibial surface of the bilateral lower extremity on the 8th day of his hospitalization (Table 2) . He was treated with ceftriaxone, macrolide, teicoplanin, azithromycin, favipiravir, clexane, dexamethasone, and interferon-alpha treatment. Erythema nodosum was observed one day after the termination of the interferon treatment. The patient showed improvement in one day without termination of any other treatment (patient four).

Two patients with a diagnosis of MIS-C had rashes. The first MIS-C patient had high and persistent fever, bilateral non-purulent conjunctivitis, polymorphic rash in the trunk and gluteal area, strawberry tongue, and palmoplantar erythema. Rashes began after the second day of cefixime and after 3 days of abdominal pain, diarrhea, and fever. We terminated the usage of the drug (patient twelve).

The second patient with MIS-C had fever, vomiting, and abdominal pain on the fourth day. Bilateral conjunctivitis, maculopapular exanthemas on trunk, gluteal region, and bilateral axilla developed after 3 days of the outset of COVID-19 symptoms. The patient did not have a history of drug usage ( Table 2 ).

The patients were discharged when they were healed, and one of them was deceased (SJS). Whitaker and et al reported that 30 of the 58 children patients who were diagnosed as MIS-C had erythematous rashes. 10 In genetically predisposed individuals, SARS-CoV-2 can trigger the development of a rapid autoimmune and/or autoinflammatory dysregulation and lead to severe interstitial pneumonia. 11 

The authors have no conflicts of interest to declare.

Cutaneous manifestations in COVID-19: a first perspective

Extrapulmonary manifestations of COVID-19 in children: a comprehensive review and pathophysiological considerations

Clinical characteristics of coronavirus disease 2019 in China

Cutaneous manifestation of COVID-19: an evidence-based review

Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome

Cutaneous manifestations in COVID-19: a first perspective " by Recalcati S

COVID-19 can present with a rash and be mistaken for Dengue": Petechial rash in a patient with COVID-19 infection

DRESS syndrome stimulating coronavirus 2019-NcoV disease

Cutaneous manifestations of COVID-19: a systematic review

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Could SARS-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?

Two false negative test results in a symptomatic patient with a confirmed case of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)